Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|February 19, 2026

BioPharm International Sponsored eBooks

  • BioPharm International Sponsored eBooks-2-19-26

Advanced Analytical Methods for Host Cell Impurities

This eBook explores the growing analytical challenges of managing host cell protein (HCP) impurities in biopharmaceutical manufacturing, with particular focus on complex biologics such as gene therapies and CHO-derived products. It examines the evolution of HCP analytics from early ELISA and Western blot methods to advanced orthogonal approaches combining Antibody Affinity Extraction (AAE™) with mass spectrometry, which enable more precise identification, coverage analysis, and absolute quantification of high-risk HCPs. A featured study demonstrates the utility of a parallel reaction monitoring (PRM) assay using stable isotope-labeled peptides to quantify six CHO HCP lipases at sub-ppm detection levels.

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.